Revolutionizing Brain Health across Rare and Common Neurological Disorders

Voxel Therapeutics is building a precision therapeutics platform that discovers and develops therapeutic modalities capable of toggling gene regulation—either increasing or decreasing gene expression—through targeted gene editing and RNA-based approaches. Our platform is designed to address diseases driven by both loss-of-function and gain-of-function mechanisms by restoring gene activity to its optimal physiological range.

At the core of Voxel is a modality-agnostic discovery engine that identifies the most effective strategy for each disease, whether through programmable gene editing, epigenetic editing, RNA-targeting technologies, antisense oligonucleotides (ASOs), or other next-generation regulatory approaches. Rather than forcing every disease into a single therapeutic modality, we match the technology to the underlying biology, enabling precise, durable, and potentially transformative treatments.

Beyond therapeutic discovery, Voxel serves as a strategic development partner for patient foundations, biotechnology companies, and academic investigators seeking to translate scientific discoveries into clinical programs. Our team brings deep expertise across target discovery, computational biology, biomarker development, translational science, preclinical strategy, regulatory planning, and clinical trial readiness. We work alongside our partners to de-risk development, prioritize the right therapeutic modality, and accelerate programs from concept through IND-enabling studies and into the clinic.

We begin where the unmet need is greatest—in rare genetic diseases—where understanding disease biology can rapidly translate into impactful therapies. Through close collaboration with patient organizations, academic institutions, and industry partners, we integrate human genetics, multi-omics data, and clinical insights to develop therapies grounded in real patient biology.

The knowledge and technologies generated through these partnerships create a scalable platform that extends beyond rare disease. By developing programmable approaches to precisely control gene expression, Voxel is building a new class of therapeutics capable of treating a broad range of genetic and neurological disorders while providing partners with the scientific and translational expertise needed to successfully bring these therapies to patients.